12 Best Stocks to Invest in for a Stock Market Game

4. Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Price momentum over the past year: 136.15%

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is a biopharmaceutical company focused on developing and marketing therapies in Illinois. The core offerings of the company include Gvoke, Keveyis, and Recorlev, with a series of development programs to expand the approved uses of its commercialized products and the introduction of new ones through its proprietary technology platforms, XeriSol and XeriJect. Incepted in 2005, the company finds solutions to current medical problems through its innovative products and partnerships.

Just in, Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has received approval for its supplemental new drug application (sNDA) of Gvoke VialDx™ from the U.S. Food and Drug Administration (FDA). This has initiated a partnership with American Regent for commercialization in the U.S. While entering a growing procedural gastroenterology market, with 20 million gastrointestinal endoscopic procedures carried out annually, Xeris will be handling product supply. At the same time, American Regent will oversee the commercialization segment.

In the recent financials, Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) announced a 20% plus revenue growth for thirteen consecutive quarters. The projection for 2025 is equally promising, with a growth of over 30% from the 2024 levels. This upward trend is mainly attributed to Recorlev, or as the company calls it, the “flagship product,” which has a small market of around 10 to 15 million patients per million in the United States, targeted by few. Steve Pieper, the CFO at Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), made the following comment:

“Given our strong topline growth expectations, our healthy and improving gross margin profile, our disciplined expense management, and strong cash position, it is clear that Xeris will turn an important financial corner in 2025 that will position the company to execute on its priorities without the need to dilute shareholders”

All praise to the new management, 2024 was an unprecedented year of excellent commercial execution, robust pipeline development, and disciplined capital management. Moving to 2025, the company considers Recorlev and Gvoke to be its growth drivers, with demand rising above the 2024 figures. At this time, it is important to hold on to this stock.